Lisotti Andrea, Crinò Stefano Francesco, Mangiavillano Benedetto, Cominardi Anna, Ofosu Andrew, Brighi Nicole, Metelli Flavio, Zagari Rocco Maurizio, Facciorusso Antonio, Fusaroli Pietro
Gastroenterology Unit, Hospital of Imola, University of Bologna, Imola, Italy.
Department of Medicine, Gastroenterology and Digestive Endoscopy Unit, The Pancreas Institute, University Hospital of Verona, Verona, Italy.
Gastroenterol Rep (Oxf). 2022 May 26;10:goac022. doi: 10.1093/gastro/goac022. eCollection 2022.
Focal splenic lesions are usually incidentally discovered on radiological assessments. Although percutaneous tissue acquisition (TA) under trans-abdominal ultrasound guidance is a well-established technique for obtaining cyto-histological diagnosis of focal splenic lesions, endoscopic ultrasound (EUS)-guided TA has been described in several studies, reporting different safety and outcomes. The aim was to assess the pooled safety, adequacy, and accuracy of EUS-TA of splenic lesions.
A comprehensive review of available evidence was conducted at the end of November 2021. All studies including more than five patients and reporting about the safety, adequacy, and accuracy of EUS-TA of the spleen were included.
Six studies (62 patients) were identified; all studies have been conducted using fine-needle aspiration (FNA) needles. Pooled specimen adequacy and accuracy of EUS-TA for spleen characterization were 92.8% [95% confidence interval (CI), 86.3%-99.3%] and 88.2% (95% CI, 79.3%-97.1%), respectively. The pooled incidence of adverse events (six studies, 62 patients) was 4.7% (95% CI, 0.4%-9.7%).
EUS-FNA of the spleen is a safe technique with high diagnostic adequacy and accuracy. The EUS-guided approach could be considered a valid alternative to the percutaneous approach for spleen TA.
局灶性脾病变通常在影像学评估时偶然发现。尽管经腹超声引导下经皮组织获取(TA)是获取局灶性脾病变细胞组织学诊断的成熟技术,但内镜超声(EUS)引导下TA已在多项研究中有所描述,报告了不同的安全性和结果。目的是评估EUS引导下脾病变TA的综合安全性、充分性和准确性。
2021年11月底对现有证据进行了全面综述。纳入所有纳入超过5例患者并报告EUS引导下脾TA安全性、充分性和准确性的研究。
共纳入6项研究(62例患者);所有研究均使用细针穿刺(FNA)针进行。EUS引导下脾病变TA的标本综合充分性和准确性分别为92.8%[95%置信区间(CI),86.3%-99.3%]和88.2%(95%CI,79.3%-97.1%)。不良事件的综合发生率(6项研究,62例患者)为4.7%(95%CI,0.4%-9.7%)。
EUS引导下脾FNA是一种安全的技术,具有较高的诊断充分性和准确性。EUS引导的方法可被视为脾TA经皮方法的有效替代方案。